Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 11;13(8):2214.
doi: 10.3390/jcm13082214.

Optic Nerve Neuroprotection in Glaucoma: A Narrative Review

Angela D'Angelo  1 , Livio Vitiello  2 , Filippo Lixi  3 , Giulia Abbinante  2 , Alessia Coppola  2 , Vincenzo Gagliardi  2 , Alfonso Pellegrino  2 , Giuseppe Giannaccare  3
Affiliations
Review

Optic Nerve Neuroprotection in Glaucoma: A Narrative Review

Angela D'Angelo et al. J Clin Med. .

Abstract

In recent years, researchers have been interested in neuroprotective therapies as a cutting-edge therapeutic strategy to treat neurodegenerative disorders by shielding the brain system from harmful events. Millions of individuals worldwide suffer from glaucoma, an ocular neurodegenerative disease characterized by gradual excavation of the optic nerve head, retinal axonal damage, and consequent visual loss. The pathology's molecular cause is still mostly unknown, and the current treatments are not able to alter the disease's natural progression. Thus, the modern approach to treating glaucoma consists of prescribing medications with neuroprotective properties, in line with the treatment strategy suggested for other neurodegenerative diseases. For this reason, several naturally derived compounds, including nicotinamide and citicoline, have been studied throughout time to try to improve glaucoma management by exploiting their neuroprotective properties. The purpose of this review is to examine the naturally derived compounds that are currently utilized in clinical practice for neuroprotection in glaucomatous patients based on scientific data, emphasizing these compounds' pivotal mechanism of action as well as their proven therapeutic and neuroprotective benefits.

Keywords: glaucoma; neurodegenerative diseases; neuroprotection; optic nerve.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Boccaccini A., Cavaterra D., Carnevale C., Tanga L., Marini S., Bocedi A., Lacal P.M., Manni G., Graziani G., Sbardella D., et al. Novel frontiers in neuroprotective therapies in glaucoma: Molecular and clinical aspects. Mol. Asp. Med. 2023;94:101225. doi: 10.1016/j.mam.2023.101225. - DOI - PubMed
    1. Tham Y.-C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090. doi: 10.1016/j.ophtha.2014.05.013. - DOI - PubMed
    1. Chitu I., Tudosescu R., Leasu-Branet C., Voinea L.-M. Citicoline—A neuroprotector with proven effects on glaucomatous disease. Romanian J. Ophthalmol. 2017;61:152–158. doi: 10.22336/rjo.2017.29. - DOI - PMC - PubMed
    1. Parisi V., Centofanti M., Ziccardi L., Tanga L., Michelessi M., Roberti G., Manni G. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefe’s Arch. Clin. Exp. Ophthalmol. 2015;253:1327–1340. doi: 10.1007/s00417-015-3044-9. - DOI - PubMed
    1. Villoslada P., Steinman L. New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. Expert Opin. Investig. Drugs. 2020;29:443–459. doi: 10.1080/13543784.2020.1757647. - DOI - PubMed